Anthracycline cardiomyopathy in anesthesiology
نویسندگان
چکیده
منابع مشابه
Carvedilol for anthracycline cardiomyopathy prevention.
alay et al. (1), in a population of apparently unselected patients eceiving their first 6 cycles of anthracyclines, found in their ontrol group a high incidence of functional cardiomyopathy: 24% f their patients had at the final examination an ejection fraction of 0% or less. This incidence of cardiac dysfunction is higher than he expected one for patients beginning their exposure to anthraycli...
متن کاملManagement options Anthracycline-induced cardiomyopathy
Anthracycline cardiomyopathy is less frequently encountered nowadays, due to the well-recognised dose limitations and cardiac monitoring protocols used by chemotherapy centres. However, it is a condition that will persist due to the sensitivity of some patients to these drugs and the necessity for large doses to be used for certain individuals. We have demonstrated the benefit of angiotensin-co...
متن کاملAnthracycline-induced cardiomyopathy in siblings with early breast cancer.
A 41-year-old woman with no significant previous medical or family history underwent a left wide local excision (WLE) and axillary node clearance for a 9-mm grade 3 IDC, node-negative breast cancer. The tumour was estrogen receptor (ER), progesterone receptor (PgR) and HER-2 negative. She received six cycles of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC 75, ...
متن کاملEfficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.
m g o d 0 m v s To the Editor: Antineoplastic agents of the anthracycline (ANT) group are commonly and effectively used in various forms of malignancies. Anthracyclines might lead to irreversible cardiomyopathy (CMP), despite their beneficial effects. A number of mechanisms, such as elevation in free superoxide anion radicals, apoptosis, and mitochondrial dysfunction have been implicated in ANT...
متن کاملPotential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy
OBJECTIVE Anthracyclines are successfully used in cancer treatment, but their use is limited by their cardiotoxic side effects. Several risk factors for anthracycline-associated cardiomyopathy (AACM) are known, yet the occurrence of AACM in the absence of these known risk factors suggests that other factors must play a role. The purpose of this study was to evaluate whether a genetic predisposi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archiv Euromedica
سال: 2019
ISSN: 2199-885X
DOI: 10.35630/2199-885x/2019/9/3.10